Halozyme Q3 2023 Financial Results & ENHANZE Updates

Halozyme Therapeutics reported third quarter 2023 financial and operating results, highlighting progress with its ENHANZE drug delivery technology platform and auto-injector business. The company announced a $250 million accelerated share repurchase program and discussed forward-looking expectations for revenue growth, profitability, and strategic partnerships driving ENHANZE adoption across therapeutic applications.